Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Rubraca (rucaparib) is a PARP inhibitor that was approved in 2016 to treat women with advanced ovarian cancer who have had two or more prior treatment and who have inherited mutations in BRCA or whose tumors have BRCA mutations as detected by the FoundationFocus CDxBRCA companion diagnostic.
The ARIEL (the Assessment of Rucaparib In Ovarian CancEr TriaL)4 clinical trial currently enrolling patients with ovarian cancer, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation and who have had at least two other chemotherapy regimens. ARIEL4 will test Rubraca against standard of care therapy.
The phase III ARIEL3 study is ongoing but no longer enrolling patients. ARIEL3 tests rucaparib as maintenance therapy (therapy given after treatment is completed when women would typically not be on any treatment) in relapsed ovarian cancer in two groups: women with and without BRCA mutations. ARIEL3 will evaluate the utility of this tumor test to predict the response in women without BRCA mutations. In ARIEL3, two-thirds of women will receive rucaparib, while the remaining third will be given a placebo following response to platinum chemotherapy.